ATG2A and nasopharyngeal carcinoma: Conversely, in EBV-positive NPC patients, the positivity rates were as follows: ATG1 (28 patients, 93.33%); ATG2A (0 patients, 0%); ATG2B (21 patients, 70%); ATG3 (28 patients, 93.33%); ATG4A (29 patients, 96.67%); ATG4B (19 patients, 63.33%); ATG4C (22 patients, 73.33%); ATG4D (2 patients, 6.67%); and ATG5 (30 patients, 100%).